Cargando…
Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
Inhalation-administrated drugs remain an interesting possibility of addressing pulmonary diseases. Direct drug delivery to the lungs allows one to obtain high concentration in the site of action with limited systemic distribution, leading to a more effective therapy with reduced required doses and s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845529/ https://www.ncbi.nlm.nih.gov/pubmed/36683752 http://dx.doi.org/10.1093/rb/rbac099 |
_version_ | 1784870921003073536 |
---|---|
author | Knap, Karolina Kwiecień, Konrad Reczyńska-Kolman, Katarzyna Pamuła, Elżbieta |
author_facet | Knap, Karolina Kwiecień, Konrad Reczyńska-Kolman, Katarzyna Pamuła, Elżbieta |
author_sort | Knap, Karolina |
collection | PubMed |
description | Inhalation-administrated drugs remain an interesting possibility of addressing pulmonary diseases. Direct drug delivery to the lungs allows one to obtain high concentration in the site of action with limited systemic distribution, leading to a more effective therapy with reduced required doses and side effects. On the other hand, there are several difficulties in obtaining a formulation that would meet all the criteria related to physicochemical, aerodynamic and biological properties, which is the reason why only very few of the investigated systems can reach the clinical trial phase and proceed to everyday use as a result. Therefore, we focused on powders consisting of polysaccharides, lipids, proteins or natural and synthetic polymers in the form of microparticles that are delivered by inhalation to the lungs as drug carriers. We summarized the most common trends in research today to provide the best dry powders in the right fraction for inhalation that would be able to release the drug before being removed by natural mechanisms. This review article addresses the most common manufacturing methods with novel modifications, pros and cons of different materials, drug loading capacities with release profiles, and biological properties such as cytocompatibility, bactericidal or anticancer properties. |
format | Online Article Text |
id | pubmed-9845529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98455292023-01-19 Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations Knap, Karolina Kwiecień, Konrad Reczyńska-Kolman, Katarzyna Pamuła, Elżbieta Regen Biomater Review Inhalation-administrated drugs remain an interesting possibility of addressing pulmonary diseases. Direct drug delivery to the lungs allows one to obtain high concentration in the site of action with limited systemic distribution, leading to a more effective therapy with reduced required doses and side effects. On the other hand, there are several difficulties in obtaining a formulation that would meet all the criteria related to physicochemical, aerodynamic and biological properties, which is the reason why only very few of the investigated systems can reach the clinical trial phase and proceed to everyday use as a result. Therefore, we focused on powders consisting of polysaccharides, lipids, proteins or natural and synthetic polymers in the form of microparticles that are delivered by inhalation to the lungs as drug carriers. We summarized the most common trends in research today to provide the best dry powders in the right fraction for inhalation that would be able to release the drug before being removed by natural mechanisms. This review article addresses the most common manufacturing methods with novel modifications, pros and cons of different materials, drug loading capacities with release profiles, and biological properties such as cytocompatibility, bactericidal or anticancer properties. Oxford University Press 2022-12-08 /pmc/articles/PMC9845529/ /pubmed/36683752 http://dx.doi.org/10.1093/rb/rbac099 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Knap, Karolina Kwiecień, Konrad Reczyńska-Kolman, Katarzyna Pamuła, Elżbieta Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations |
title | Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations |
title_full | Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations |
title_fullStr | Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations |
title_full_unstemmed | Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations |
title_short | Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations |
title_sort | inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845529/ https://www.ncbi.nlm.nih.gov/pubmed/36683752 http://dx.doi.org/10.1093/rb/rbac099 |
work_keys_str_mv | AT knapkarolina inhalablemicroparticlesasdrugdeliverysystemstothelungsinadrypowderformulations AT kwiecienkonrad inhalablemicroparticlesasdrugdeliverysystemstothelungsinadrypowderformulations AT reczynskakolmankatarzyna inhalablemicroparticlesasdrugdeliverysystemstothelungsinadrypowderformulations AT pamułaelzbieta inhalablemicroparticlesasdrugdeliverysystemstothelungsinadrypowderformulations |